Vaccinex Inc VCNX Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.00 up $0.08, 8.70% at close Nov 6
Last close · Previous close $0.92
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.00down $0.11, 10.07%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.92Nov 5
- Volume806.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume441.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.31 to $1.50; now $1.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VCNX beat the S&P 500 in 1 of 6 periods.
| Period | VCNX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VCNX: down 10.1% S&P 500: down 5.6% | VCNX trailed the S&P 500 by 4.5 percentage points Trailed |
| 3M | VCNX: down 10.7% S&P 500: down 4.1% | VCNX trailed the S&P 500 by 6.6 percentage points Trailed |
| YTD | VCNX: down 7.0% S&P 500: up 8.7% | VCNX trailed the S&P 500 by 15.7 percentage points Trailed |
| 1Y | VCNX: up 120.1% S&P 500: up 10.9% | VCNX beat the S&P 500 by 109.2 percentage points Beat |
| Long term | ||
| 3Y | VCNX: down 92.3% S&P 500: up 75.0% −57.5% vs +20.5% a year | VCNX trailed the S&P 500 by 167.3 percentage points Trailed |
| 5Y | VCNX: down 99.8% S&P 500: up 67.8% −70.2% vs +10.9% a year | VCNX trailed the S&P 500 by 167.6 percentage points Trailed |
$10,000 invested in VCNX 5 years ago (Nov 5, 2021) would be worth about $24 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
VCNX beat the S&P 500 in 1 of 6 periods.
| Period | VCNX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VCNX: down 10.1% S&P 500: down 5.6% | VCNX trailed the S&P 500 by 4.5 percentage points Trailed |
| 3M | VCNX: down 10.7% S&P 500: down 4.3% | VCNX trailed the S&P 500 by 6.4 percentage points Trailed |
| YTD | VCNX: down 7.0% S&P 500: up 7.8% | VCNX trailed the S&P 500 by 14.8 percentage points Trailed |
| 1Y | VCNX: up 120.1% S&P 500: up 9.7% | VCNX beat the S&P 500 by 110.4 percentage points Beat |
| Long term | ||
| 3Y | VCNX: down 92.3% S&P 500: up 68.8% −57.5% vs +19.1% a year | VCNX trailed the S&P 500 by 161.1 percentage points Trailed |
| 5Y | VCNX: down 99.8% S&P 500: up 56.9% −70.2% vs +9.4% a year | VCNX trailed the S&P 500 by 156.7 percentage points Trailed |
$10,000 invested in VCNX 5 years ago (Nov 5, 2021) would be worth about $24 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$2,444.40
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Aug 9, 2018.
Stock splits
2
Latest: 1-for-14 on . Share counts adjust after each split.
Both splits
- 1-for-14
- 1-for-15
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY24, the quarter ended Sep 30, 2024. “Last 12 months” means the four quarters from Oct 1, 2023 to Sep 30, 2024, and balance-sheet figures are as of Sep 30, 2024.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $388.00Kdown 51.2%
- Net income
- −$18.58M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY22 (Dec 31, 2022) | $225.00K | −$5.08M | Paused See the note under the price. |
| Q1 FY23 (Mar 31, 2023) | $550.00K | −$4.96M | Paused See the note under the price. |
| Q2 FY23 (Jun 30, 2023) | $0.00 | −$7.06M | Paused See the note under the price. |
| Q3 FY23 (Sep 30, 2023) | $20.00K | −$4.91M | Paused See the note under the price. |
| Q4 FY23 (Dec 31, 2023) | $0.00 | −$3.32M | Paused See the note under the price. |
| Q1 FY24 (Mar 31, 2024) | $104.00K | −$3.90M | Paused See the note under the price. |
| Q2 FY24 (Jun 30, 2024) | $232.00K | −$5.63M | Paused See the note under the price. |
| Q3 FY24 (Sep 30, 2024) | $52.00K | −$5.73M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $625.00K | −$28.85M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $900.00K | −$22.38M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $275.00K | −$19.82M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $570.00K | −$20.25M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −5,241.2%
- Net −4,787.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$15.87MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$15.85MLast 12 months
- Capital spending$22.00KLast 12 months
- −4,089.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $15.91MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.92MAs of Sep 30, 2024
Cash plus short- and long-term marketable securities on the Sep 30, 2024 balance sheet.
- Total debt$59.00KAs of Sep 30, 2024
- Net cash$2.86MAs of Sep 30, 2024
- Book value per sharePausedAs of Sep 30, 2024
See the note under the price. - 0.77As of Sep 30, 2024
Current assets divided by current liabilities on the Sep 30, 2024 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −407.9%Last 12 months
Over the last 12 months, Vaccinex’s net loss was 407.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Vaccinex Inc
Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents immune infiltration into tumors. Pepinemab was studied as a monotherapy in the Phase 1/2a SIGNAL-AD study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
VCNX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VCNX stock FAQ
What is VCNX stock’s price today?
Vaccinex (VCNX) traded at $1.00 at the close on , up $0.08 (8.70%) from the previous close of $0.92. Over the past 52 weeks it has traded between $0.31 and $1.50.
If you invested $1,000 in VCNX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VCNX on would be worth about $2 at the close on , a total return of −99.8%. The same $1,000 would be worth $2,201 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does Vaccinex make?
Vaccinex reported $388.0 thousand of revenue over the four quarters to , down 51.2% from the twelve months before. In its latest quarter (Q3 FY24, ended ) revenue was $52.0 thousand, up 160.0% from a year earlier.
Is Vaccinex profitable?
Not over the four quarters to . Vaccinex reported a net loss of $18.6 million across those four quarters on $388.0 thousand of revenue.
Does VCNX pay a dividend?
Vaccinex hasn’t paid a dividend in the last twelve months.
What is VCNX’s 52-week high and low?
Over the past 52 weeks VCNX has traded as low as $0.31 and as high as $1.50. At $1.00 at the close on , it is 33.3% below that high and 222.6% above the low.
What is VCNX’s all-time high?
VCNX’s highest closing price was $2,444.40 on , adjusted for stock splits. At $1.00 at the close on , it is 100.0% below that record.
Has VCNX stock ever split?
Yes, twice: 1-for-15 on ; 1-for-14 on .
How has VCNX stock performed?
Including dividends and measured to the close on , VCNX has returned −7.0% so far this year and +120.1% over the past year, and −99.8% over five years (−70.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Vaccinex in?
Vaccinex is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does VCNX trade on?
Vaccinex trades on the PINK under the ticker symbol VCNX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.